The earnings call for Alkermes highlighted strong financial performance and promising clinical trial results for alixorexton, particularly in addressing wakefulness, fatigue, and cognition in narcolepsy type 1. However, increased R&D expenses and uncertainty regarding the cataplexy data, alongside market concerns about visual adverse events, present challenges. Despite these, the overall sentiment is positive due to the company's financial strength and clinical progress.

Company Guidance -

Q3 2025

During the Alkermes second quarter 2025 financial results conference call, the company provided a robust outlook on its financial and operational performance. They reported total revenues of $390.7 million, with a significant 14% year-over-year growth in proprietary product net sales, reaching $307.2 million. Key drivers included a $9 million one-time gross-to-net benefit from VIVITROL and an $11 million benefit from ARISTADA. Manufacturing and royalty revenues were $83.4 million, including $39.4 million from VUMERITY. The company maintained a strong balance sheet, ending the quarter with $1.05 billion in cash and investments. For the full year 2025, Alkermes expects proprietary product net sales to exceed $1 billion, positioning them to potentially end the year at the high end of their financial guidance. Additionally, they highlighted the promising clinical results of alixorexton, their lead orexin candidate for treating narcolepsy, providing a solid foundation for future growth.

Strong Financial Performance

Alkermes reported total revenues of $390.7 million, with proprietary product net sales of $307.2 million, reflecting a 14% year-over-year growth. The company also achieved GAAP net income of $87.1 million, EBITDA of $101.6 million, and adjusted EBITDA of $126.5 million.

Positive Clinical Trial Results for Alixorexton

The Phase II Vibrance 1 study for alixorexton in narcolepsy type 1 showed significant effects on wakefulness, improvements in fatigue and cognition, and a generally well-tolerated profile.

Strong Balance Sheet

The company ended the quarter with $1.05 billion in cash and total investments, with no debt and a $200 million share repurchase authorization.

Expansion of Orexin Portfolio

Alkermes initiated first-in-human studies for ALKS 4510 and plans to advance ALKS 7290 into the clinic, aiming to address conditions beyond central disorders of hypersomnia.

Alkermes (ALKS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ALKS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 22, 2025	2025 (Q3)	0.40 / -	0.72	―	―	―
Jul 29, 2025	2025 (Q2)	0.36 / 0.67	0.7	-4.57% (-0.03)
May 01, 2025	2025 (Q1)	0.25 / 0.27	0.43	-38.37% (-0.16)
Feb 12, 2025	2024 (Q4)	0.76 / 1.05	0.22	377.27% (+0.83)
Oct 24, 2024	2024 (Q3)	0.70 / 0.72	0.595	21.01% (+0.13)
Jul 24, 2024	2024 (Q2)	0.70 / 0.70	0.511	36.99% (+0.19)
May 01, 2024	2024 (Q1)	0.58 / 0.43	0.009	4677.78% (+0.42)
Feb 15, 2024	2023 (Q4)	0.45 / 0.22	0.13	69.23% (+0.09)
Oct 25, 2023	2023 (Q3)	0.40 / 0.59	0.019	3031.58% (+0.58)
Jul 26, 2023	2023 (Q2)	0.37 / 0.51	0.056	812.50% (+0.46)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ALKS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 29, 2025	$26.15	$27.00	+3.25%
May 01, 2025	$28.77	$30.58	+6.29%
Feb 12, 2025	$31.96	$33.50	+4.82%
Oct 24, 2024	$27.85	$26.85	-3.59%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Alkermes (ALKS) report earnings?

Alkermes (ALKS) is schdueled to report earning on Oct 22, 2025, Before Open (Confirmed).

What is Alkermes (ALKS) earnings time?

Alkermes (ALKS) earnings time is at Oct 22, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ALKS EPS forecast?

ALKS EPS forecast for the fiscal quarter 2025 (Q3) is 0.4.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing